The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Toxins and drug discovery
Open accessAbstract
Components from venoms have stimulated many drug discovery projects, with some notable successes. These are briefly reviewed, from captopril to ziconotide. However, there have been many more disappointments on the road from toxin discovery to approval of a new medicine. Drug discovery and development is an inherently risky business, and the main causes of failure during development programmes are outlined in order to highlight steps that might be taken to increase the chances of success with toxin-based drug discovery. These include having a clear focus on unmet therapeutic needs, concentrating on targets that are well-validated in terms of their relevance to the disease in question, making use of phenotypic screening rather than molecular-based assays, and working with development partners with the resources required for the long and expensive development process.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Natural products as sources of new drugs from 1981 to 2014
Newman, D. J., & Cragg, G. M. (2016) · Journal of Natural Products · doi:10.1021/acs.jnatprod.5b01055 · Cited by 5,858
Natural products as sources of new drugs over the last 25 years
Newman, D. J., & Cragg, G. M. (2007) · Journal of Natural Products · doi:10.1021/np068054v · Cited by 5,517
Natural products as sources of new drugs over the 30 years from 1981 to 2010
Newman, D. J., & Cragg, G. M. (2012) · Journal of Natural Products · doi:10.1021/np200906s · Cited by 4,687
Can the pharmaceutical industry reduce attrition rates?
Kola, I., & Landis, J. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1470 · Cited by 4,167
Diagnosing the decline in pharmaceutical R&D efficiency
Scannell, J. W., Blanckley, A., Boldon, H., & Warrington, B. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3681 · Cited by 1,981
How were new medicines discovered?
Swinney, D. C., & Anthony, J. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3480 · Cited by 1,812
Lessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework
Cook, D., Brown, D., Alexander, R., March, R., Morgan, P., Satterthwaite, G., & Pangalos, M. N. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4309 · Cited by 1,344
The productivity crisis in pharmaceutical R&D
Pammolli, F., Magazzini, L., & Riccaboni, M. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3405 · Cited by 918
Phase II and Phase III attrition rates 2011–2012
Arrowsmith, J., & Miller, P. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd4090 · Cited by 697 · cited 1×
“…be possible to screen for novel activities using model organisms (such as nematodes (Caenorhabditis elegans) and zebrafish (Danio rerio) that have found some use in other drug discovery projects (Giacomotto and S egalat, 2010; Delvecchio et al., 2011; Asnani and Peterson, 2014; Bruni et al., 2014).”
BackgroundThe discovery of first-in-class drugs: origins and evolution
Eder, J., Sedrani, R., & Wiesmann, C. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4336 · Cited by 514
Cited by
Bordon, K. D. C. F., Cologna, C. T., Fornari-Baldo, E. C., Pinheiro-Júnior, E. L., Cerni, F. A., Amorim, F. G., Anjolette, F. A. P., Cordeiro, F. A., Wiezel, G. A., Cardoso, I. A., et al. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.01132 · Cited by 303
Peptide therapeutics from venom: Current status and potential
Pennington, M. W., Czerwinski, A., & Norton, R. S. (2018) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2017.09.029 · Cited by 278
Conotoxins: Chemistry and Biology
Jin, A.-H., Muttenthaler, M., Dutertre, S., Himaya, S. W. A., Kaas, Q., Craik, D. J., Lewis, R. J., & Alewood, P. F. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.9b00207 · Cited by 261
Molecular Display of the Animal Meta-Venome for Discovery of Novel Therapeutic Peptides
Hsiao, M.-H., Miao, Y., Liu, Z., Schütze, K., Limjunyawong, N., Chien, D. C.-C., Monteiro, W. D., Chu, L.-S., Morgenlander, W., Jayaraman, S., et al. (2025) · Molecular & Cellular Proteomics · doi:10.1016/j.mcpro.2024.100901 · Cited by 5
Metadata
- Authors
- Harvey, A. L.
- Venue
- Toxicon
- Publisher
- Elsevier BV
- Published
- 2014-12
- Volume
- 92
- Pages
- 193-200
- ISSN
- 0041-0101 (ISSN-L)
- OpenAlex
- W2061781519
- Cited by
- 210
- References
- 13
- FWCI
- 10.70
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Toxins and drug discovery. https://app.cochat.ai/papers/10.1016/j.toxicon.2014.10.020
- The paper
- Harvey, A. L. (2014). Toxins and drug discovery. Toxicon. https://doi.org/10.1016/j.toxicon.2014.10.020
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.